Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.

Chinn, Paul; Leonard, John E.; Rosenberg, J.; Hanna, Nabil; Anderson, Darrell R.

doi:10.3892/ijo.15.5.1017

Cited by 47 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…O estudo da estabilidade do anticorpo marcado é um parâmetro de extrema importância no desenvolvimento de radiofármacos, devendo ser considerado o tempo entre o preparo, dispensação, transporte, até a eventual administração ao paciente [23,72,81]. No entanto, evitar ou reduzir ao mínimo a degradação radiolítica de compostos radiomarcados para uso em terapia considera-se como um dos principais desafios para os pesquisadores na formulação de radiofármacos, pois, os efeitos deletérios atribuídos à radiólise comprometem a eficácia terapêutica dessas formulações [74,[77][78][79][80]. Na primeira condição de estudo de estabilidade, o anticorpo anti-CD20 marcado com atividade terapêutica foi incubado em plasma humano e a estabilidade determinada 2, 4, 6, e 24 hs após incubação.…”

Section: Discussionunclassified

“…Em geral, a ocorrência de autoradiólise em compostos radiomarcados é um fato preocupante, pois isso comprometerá a sua capacidade e eficiência terapêutica. Minimizar os efeitos deletérios atribuídos à radiólise de compostos radiomarcados por iodo-131 e ítrio-90, ou outros radioisótopos beta emissores, é de suma importância na preparação de formulações clínicas para radioimunoterapia [23,[77][78][79][80]. A radiólise pode ocorrer e se manifestar como problema tanto durante o processo de marcação como durante armazenamento do composto radiomarcado até sua administração ao paciente.…”

Section: Radiólise Do Anticorpo Marcadounclassified

“…Ensaio Após a marcação, o produto (anticorpo anti-CD20-131 I) foi transferido ao frasco contendo a solução de ácido gentísico já preparada, e a mistura foi conservada em geladeira (2 -8ºC). Em seguida, verificou-se a estabilidade dos compostos por meio da determinação de pureza radioquímica (%) duas, quatro, seis, e 24 horas após a incubação por meio de cromatografia em fitas (duplicatas) de sílica gel (ITLC-SG) [23,74,78,81].…”

Section: Preparação De Solução Estabilizadora De áCido Gentísicounclassified

“…Em seguida, verificou-se a estabilidade dos compostos por meio da determinação de pureza radioquímica (%) duas, quatro, seis, e 24 horas após a incubação por meio de cromatografia em fitas (duplicatas) de sílica gel (ITLC-SG) [23,74,78,81]. Vale ressaltar que este ensaio foi realizado somente com o anticorpo anti-CD20 marcado com atividade terapêutica de 2960 MBq.…”

Section: Estudo De Estabilidade Em Solução Estabilizadora De áCido Geunclassified

See 3 more Smart Citations

"Estudo de marcação com Iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma não-Hodgkin"

Akanji¹

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: Radiólise Do Anticorpo Marcadounclassified

Section: Preparação De Solução Estabilizadora De áCido Gentísicounclassified

Section: Estudo De Estabilidade Em Solução Estabilizadora De áCido Geunclassified

See 2 more Smart Citations

"Estudo de marcação com Iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma não-Hodgkin"

Akanji¹

View full text Add to dashboard Cite

“…More recently, 90 Y-Zevalin R was proposed for the treatment of non-Hodgkin's lymphoma (Wiseman et al 1999, Wiseman et al 2000. Preclinical studies demonstrated that 111 In-Zevalin R and 90 Y-Zevalin R have similar biodistributions (Gansow et al 1991, Chinn et al 1999 (Dewaraja et al 2000, Soret et al 2003. For instance, Monte Carlo simulations are extremely useful for studying and optimizing scatter correction methods, as simulations are the only mean to separate unscattered from scattered photons.…”

Section: Introductionmentioning

confidence: 99%

Validation of the Monte Carlo simulator GATE for indium-111 imaging

et al. 2005

View full text Add to dashboard Cite

Monte Carlo simulations are useful for optimizing and assessing single photon emission computed tomography (SPECT) protocols, especially when aiming at measuring quantitative parameters from SPECT images. Before Monte Carlo simulated data can be trusted, the simulation model must be validated. The purpose of this work was to validate the use of GATE, a new Monte Carlo simulation platform based on GEANT4, for modelling indium-111 SPECT data, the quantification of which is of foremost importance for dosimetric studies. To that end, acquisitions of 111 In line sources in air and in water and of a cylindrical phantom were performed, together with the corresponding simulations. The simulation model included Monte Carlo modelling of the camera collimator and of a back-compartment accounting for photomultiplier tubes and associated electronics. Energy spectra, spatial resolution, sensitivity values, images and count profiles obtained for experimental and simulated data were compared. An excellent agreement was found between experimental and simulated energy spectra. For source-to-collimator distances varying from 0 to 20 cm, simulated and experimental spatial resolution differed by less than 2% in air, while the simulated sensitivity values were within 4% of the experimental values. The simulation of the cylindrical phantom closely reproduced the experimental data. These results suggest that GATE enables accurate simulation of 111 In SPECT acquisitions.

show abstract

Consensus conference on the use of 90‐yttrium‐ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology

et al. 2010

View full text Add to dashboard Cite

90-Yttrium-ibritumomab-tiuxetan is approved for treatment of rituximab-relapsed/refractory CD20+ follicular B-cell lymphoma and as consolidation therapy in untreated follicular lymphoma. Recommendations on the use of 90-yttrium-ibritumomab tiuxetan were issued in a consensus conference, sponsored by the Italian Society of Hematology and the Italian Association of Nuclear Medicine. Current concepts and scientific evidence on the use of 90-yttrium-ibritumomab-tiuxetan were evaluated by a panel of seven experts. The following key recommendations were issued. The most important exclusion criteria are: bone marrow infiltration by lymphoma cells and platelet count or neutrophil count lower than 100 × 109/L or 1.5 × 10 9/L. The most relevant indication for 90Y-ibritumomab- tiuxetan is as a single agent or following debulking chemotherapy for relapsed/refractory follicular lymphoma. 90Y-ibritumomab tiuxetan as a single agent is effective in improving the quality and duration of the response in follicular lymphoma after primary chemotherapy or immunochemotherapy. 90Y-ibritumomab-tiuxetan as a single agent has activity in relapsed/refractory mantle cell lymphoma and DLBCL, but the responses are of short duration. Its use after first line chemoimmunotherapy as consolidation therapy appears promising, particularly in elderly patients. The addition of 90Y-ibritumomab-tiuxetan to high-dose chemotherapy, such as BEAM, is feasible and may be recommended for patients with high-risk relapsed/refractory lymphoma. Subsequent lines of therapy can be successfully used in patients who relapse after radioimmunotherapy. © 2009 Wiley-Liss, Inc

show abstract

Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.

Cited by 47 publications

References 0 publications

"Estudo de marcação com Iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma não-Hodgkin"

"Estudo de marcação com Iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma não-Hodgkin"

Validation of the Monte Carlo simulator GATE for indium-111 imaging

Consensus conference on the use of 90‐yttrium‐ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology

Contact Info

Product

Resources

About